Search Videos and More

Showing 1 - 12 of 280 results

Previous| 1 | 2 | 3 ...24 |Next


Dana-Farber Research Publication 03.15.2024 News

Dana-Farber Research Publication 03.15.2024

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice News

Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice

Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Third Transatlantic Exchange in Oncology Conference will address Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.
BCL2 Inhibitors: What’s the Latest Research? News

BCL2 Inhibitors: What’s the Latest Research?

BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) in adults.
Dana-Farber Cancer Institute Researchers Join Global Cancer Grand Challenges Team Taking on Solid Tumors in Children News

Dana-Farber Cancer Institute Researchers Join Global Cancer Grand Challenges Team Taking on Solid Tumors in Children

Dana-Farber Cancer Institute's Scott Armstrong, MD, PhD, Benjamin Ebert, MD, PhD, Eric Fischer, PhD, Cigall Kadoch, PhD, and Kimberly Stegmaier, MD, are part of a global, interdisciplinary team of researchers, called Team PROTECT, that has been selected to receive a Cancer Grand Challenges award. The award, of up to $25 million over five years, will be used to tackle solid tumors in children.
Symposium

2024 ASCO GU Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the clinical updates you need to know from ASCO GU 2024.
Laurie H. Glimcher, MD, Selected for STAT's 2024 STATUS List News

Laurie H. Glimcher, MD, Selected for STAT's 2024 STATUS List

Laurie H. Glimcher, MD, president and CEO of Dana-Farber Cancer Institute, is named to STAT's 2024 STATUS List, featuring 50 influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech.
Dana-Farber Researchers Receive AACR 2024 Scientific Achievement Awards News

Dana-Farber Researchers Receive AACR 2024 Scientific Achievement Awards

Christopher D.M. Fletcher, MD, Timothy R. Rebbeck, PhD, David Pellman, MD, and Gordon J. Freeman, PhD, will be recognized by the American Association for Cancer Research (AACR) with 2024 Scientific Achievement Awards.
Dana-Farber CEO Laurie Glimcher Has Always Been a Trail-Blazer and a Risk-Taker News

Dana-Farber CEO Laurie Glimcher Has Always Been a Trail-Blazer and a Risk-Taker

Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.
Antibody-Drug Conjugates: A Cancer Therapy Revolution News

Antibody-Drug Conjugates: A Cancer Therapy Revolution

Dana-Farber researchers explore how a novel therapy may benefit patients
Immunotherapy for Cancer: What it Is, How it Works, and Where it’s Going News

Immunotherapy for Cancer: What it Is, How it Works, and Where it’s Going

Immunotherapy refers to treatments that use the body’s immune system to combat diseases. Immuno-oncology focuses on efforts to use the immune system as a weapon against cancer. The immune system is a collection of organs, tissues, specialized cells, and substances that protect the body against infection and disease. While the immune system can often handle very small tumors on its own, either by destroying them or keeping them from growing, it can sometimes fail — either because a tumor grows too large, the cancer cells are too well camouflaged, or the tumor cells are able to stave off an immune system attack. A key discovery, made by Dana-Farber’s Gordon Freeman, PhD, and others, was that the immune system’s attack on cancer often falls short because many cancer cells display proteins, called immune checkpoint proteins, that bring the attack to a halt.
Melanoma Vaccine: Progress and Possibility News

Melanoma Vaccine: Progress and Possibility

A melanoma therapeutic vaccine is a type of personalized cancer vaccine that is intended to train the immune system to fight cancer cells in a way that lasts many years. These novel vaccines are personally tailored to recognize the mutations present in an individual’s tumor cells. They are different from vaccines for infectious diseases, which are typically given to as many people as possible in a community to prevent a virus from spreading. Currently, no personalized melanoma vaccines are approved medicines, though several have been tested in clinical trials. A personalized RNA vaccine has recently shown promising data in patients with high-risk melanoma.  
Immunotherapy Post-Surgery Improves Overall Survival For Kidney Cancer News

Immunotherapy Post-Surgery Improves Overall Survival For Kidney Cancer

For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence, according to an analysis of results from the KEYNOTE-564 study. Pembrolizumab was associated with a 38% reduction in risk of death compared with placebo.

Showing 1 - 12 of 280 results

Previous| 1 | 2 | 3 ...24 |Next